Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Select your state to see jurisdictional framework, reporting obligations, and authority links. Substance information above is the same in every state.
A plain-language summary of the cited sources below. Informational only — not medical advice.
Sodium valproate is an anti-epilepsy medication that also treats episodes of mania. It works by blocking certain channels in nerve cells and increasing levels of a calming brain chemical called GABA (gamma-aminobutyric acid). This GABA effect is thought to help with both seizure control and mood stabilisation during manic episodes. In the body, sodium valproate typically stays active for 8 to 12 hours, though this varies between individuals.
The medication is generally used when someone's condition is stable and they would normally take it by mouth. When oral medication isn't temporarily possible, it can be given by injection into a vein, though it must never be injected into muscle as this can cause serious tissue damage.
Nausea is very common when taking sodium valproate. Tremor (shaking) is also very common. Many people experience weight gain. Some people develop low platelet counts or anaemia. These are recognised side effects your family member's doctor will be monitoring.
Serious liver problems have occurred in some patients taking sodium valproate, including liver failure that has been fatal. Inflammation of the pancreas has occurred uncommonly, sometimes with fatal outcomes, usually in the first six months of treatment. Rarely, serious skin reactions have been reported, including conditions called toxic epidermal necrolysis, Stevens Johnson Syndrome, and DRESS syndrome. Rare cases of bone marrow failure have also been reported. High ammonia levels in the blood associated with neurological symptoms have occurred in some patients.
Sodium valproate causes malformations in babies and must not be used during pregnancy unless there is no suitable alternative. Women who could become pregnant should not be prescribed this medication unless their doctor has fully explained the potential effects during pregnancy and the recommendations around its use. The medication should not be used in people with pre-existing liver problems, a family history of severe hepatitis, known allergies to it, certain enzyme or metabolic disorders, or hepatic porphyria. Sodium valproate interferes with several liver enzymes and can affect how other medications work in the body, so your family member's doctor needs to know about all medicines they take.
Common off-label uses observed in AU practice — none of these are TGA-approved indications for this substance. If the documented purpose is one of these, the prescription falls outside the TGA-approved set and may sit inside the chemical-restraint frame depending on jurisdiction and context.
These are practitioner observations, not TGA-approved indications. A use being off-label does not by itself imply a regulated restrictive practice; review the documented purpose against the observed function in context.
Tier 4 · ObservationThe condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. Clinical criteria: Treatment criteria: Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) an authorised PBS prescriber who is not a medical practitioner, but who is: (a) sharing care of the patient with at least one medical practitioner; (b) intending to share care of the patient with a medical practitioner.
“Its anticonvulsant effect is attributed to the blockade of voltage dependent Na + channels and increased brain levels of γ-aminobutyric acid (GABA). The GABA-ergic effect is also believed to possibly contribute towards the antimanic properties of sodium valproate.”
“Plasma half-life is variable but generally appears to be 8 to 12 hours (range 3.84 to 15.77 hours) in adults.”
A plain-language summary of the cited sources below. Informational only — not medical advice.
Sodium valproate is a fatty acid derivative anticonvulsant whose therapeutic effect is attributed to blockade of voltage-dependent sodium channels and increased brain levels of γ-aminobutyric acid. The GABAergic effect is believed to contribute to its antimanic properties. It is TGA-approved for treatment of epilepsy and mania in patients for whom oral therapy is temporarily not possible; PBS listing requires that the condition be stable. Plasma half-life is variable but generally 8–12 hours in adults.
Sodium valproate inhibits multiple hepatic enzymes—including cytochrome P450, glucuronyl transferase, and epoxide hydrolase—and may displace other drugs from plasma protein binding sites. Nausea and tremor are very common; weight gain, thrombocytopaenia, and anaemia are common. Hepatic dysfunction including fatal hepatic failure has occurred. Pancreatitis, sometimes lethal, has been reported uncommonly, usually within the first six months. Rare reports include bone marrow failure, toxic epidermal necrolysis, Stevens–Johnson syndrome, DRESS syndrome, and hyperammonaemia with neurological symptoms.
Contraindications include pregnancy and women of childbearing potential unless alternative treatments are unsuitable and full counselling on teratogenic risk has been provided; pre-existing or family history of severe hepatitis; known urea cycle disorders; systemic primary carnitine deficiency; hepatic porphyria; and mitochondrial disorders caused by POLG mutations. It is contraindicated in children under two years suspected of POLG-related disorder and must not be given intramuscularly.
Working under the parallel aged-care framework? Aged-care equivalent →
For prescribing by certain health practitioners Clinical criteria: Treatment criteria: Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) an authorised PBS prescriber who is not a medical practitioner, but who is: (a) sharing care of the patient with at least one medical practitioner; (b) intending to share care of the patient with a medical practitioner.
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
“Sodium valproate is an inhibitor of a variety of hepatic enzymes, including cytochrome P450, glucuronyl transferase and epoxide hydrolase, and may displace various drugs from plasma protein binding sites.”